Atrial fibrillation, or atrial fibrillation, is a common arrhythmia with a prevalence of 0.5% to 1.5% in the general population. Atrial fibrillation can be caused by many heart diseases, such as coronary heart disease, wind heart disease, myocarditis and heart failure. China is the leading country in atrial fibrillation, with about 8 million people currently suffering from atrial fibrillation. The danger of atrial fibrillation cannot be ignored. When atrial fibrillation loses its contraction function, blood is easily stagnated in the atria and forms thrombus, which can be dislodged and spread to all parts of the body, leading to cerebral embolism (stroke) and arterial embolism of the limbs (serious cases even require amputation). Stroke is one of the greatest hazards of atrial fibrillation. The incidence of stroke in patients with non-valvular atrial fibrillation is 5.6 times higher than normal, and the incidence of stroke in valvular atrial fibrillation is 17.6 times higher than normal; and the consequences of stroke caused by atrial fibrillation are more serious, with a disability rate of about 25% and a mortality rate of 25%. Stroke prevention in patients with atrial fibrillation is crucial. If sinus rhythm cannot be restored in atrial fibrillation, anticoagulants or left-ear occlusion can be used to prevent thrombosis and stroke. However, both traditional and new anticoagulants have certain limitations. First of all, looking at warfarin, long-term application of warfarin requires testing of the national standard ratio (INR), especially at the beginning of the drug, which requires repeated blood tests and cannot be adhered to by many patients in the long term. The effect of warfarin is easily influenced by other drugs or diet, and dose adjustment is not easy to master. Conversely, if there is no anticoagulation or if the attainment rate is low, then the survival rate is also significantly reduced. Therefore, it is very important to control the intensity of anticoagulation first. Internationally, 50% of anticoagulation is achieved. In our clinic, half of the patients have difficulty in maintaining stability within the standard. Long-term follow-up reveals a very high discontinuation rate, regardless of age, once they reach 5 years. About 60% of the patients could not continue to adhere to warfarin. Another 21% to 28% of patients discontinue the drug because of adverse drug reactions such as bleeding, mainly in the gastrointestinal tract. Thus, high stroke potential remains in patients with atrial fibrillation. The left auricle is thought to be the main site of thrombus formation leading to embolic events in patients with atrial fibrillation. More than 90% of left atrial thrombi in patients with non-valvular atrial fibrillation are present in the left auricle, and thrombus formation in the left auricle increases the incidence of stroke threefold. Even after the sinus rhythm is restored, the left atrial ear is depressed in contraction, which may lead to the formation of thrombus again. A better understanding of the anatomy and physiology of the left atrial ear has led to the development of surgical occlusion of the left ear and percutaneous left ear occlusion, and intervention of the left ear for stroke prevention was first written into the guidelines. Left-ear occlusion is currently a new global trend in the treatment of stroke prevention in patients with atrial fibrillation. It has a lower incidence of adverse events than warfarin anticoagulation, resulting in a greater net clinical benefit of left-ear occlusion in high-risk patients, whereas the health economics of minimally invasive surgical resection of the left ear are poor. Therefore, percutaneous left auricular occlusion is recommended for patients with atrial fibrillation who are at high risk of stroke and for whom long-term anticoagulation is contraindicated.